Jiaqi Shi

Jiaqi Shi

Auto-generated profile, based on publicly available information

Jiaqi Shi

National Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
YWYanfang Wang
Yanfang Wang
JSJiaqi Shi
Jiaqi Shi
MXMinhang Xin
Minhang Xin
AKAnna R. Kahkoska
Anna R. Kahkoska
JWJinqiang Wang
Jinqiang Wang
ZGZhen Gu
Zhen Gu

6 March 2024 in Nature Materials
Verified
Journal Article
Closed access
PDF file
JSJiaqi Shi
Jiaqi Shi
WWWei Wu
Wei Wu
DCDong Chen
Dong Chen
ZLZiyan Liao
Ziyan Liao
TSTao Sheng
Tao Sheng
ZGZhen Gu
Zhen Gu

29 March 2024 in Science Advances
Verified
Journal Article
Open access
FLFeng Liu
Feng Liu
MXMinhang Xin
Minhang Xin
HFHuiheng Feng
Huiheng Feng
WZWentao Zhang
Wentao Zhang
ZLZiyan Liao
Ziyan Liao
HLHongjun Li
Hongjun Li
Although CRISPR-mediated genome editing holds promise for cancer therapy, inadequate tumor targeting and potential off-target side effects hamper its outcomes. In this study, we present a strategy using cryo-shocked lung tumor cells as a CRISPR-Cas9 delivery system for cyclin-dependent kinase 4 ( CDK4 ) gene editing, which initiates synthetic lethal in KRAS-mutant non–small cell lung cancer (NSCLC). By rapidly liquid nitrogen shocking, we effectively eliminate the pathogenicity of tumor cells while preserving their structure and surface receptor activity. This delivery system enables the loaded CRISPR-Cas9 to efficiently target to lung through the capture in pulmonary capillaries and interactions with endothelial cells. In a NSCLC-bearing mouse model, the drug accumulation is increased nearly fourfold in lung, and intratumoral CDK4 expression is substantially down-regulated compared to CRISPR-Cas9 lipofectamine nanoparticles administration. Furthermore, CRISPR-Cas9 editing–mediated CDK4 ablation triggers synthetic lethal in KRAS-mutant NSCLC and prolongs the survival of mice.

22 November 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
CZChaojie Zhu
Chaojie Zhu
CLChao Liu
Chao Liu
QWQing Wu
Qing Wu
TSTao Sheng
Tao Sheng
RZRuyi Zhou
Ruyi Zhou
HLHongjun Li
Hongjun Li
The intricate tumor microenvironment presents formidable obstacles to the efficacy of adoptive T cell therapy in the management of solid tumors by limiting the infiltration and inducing exhaustion of the transferred T cells. Here, we developed a bacterial-based adjuvant approach that augments the efficacy of adoptive T-cell therapy for solid tumor treatment. Our study reveals that intratumor injection of E. coli MG1655 normalizes tumor vasculatures and reprograms tumor-associated macrophages into M1 phenotype that produce abundant CCL5, together facilitating tumor infiltration of adoptively transferred T cells. The depletion of tumor-associated macrophages or CCL5 neutralization in vivo leads to the significantly decreased solid tumor infiltration of adoptive T cells in the presence of bacteriotherapy. This combinatorial therapy, consisting of E. coli adjuvant and adoptive T-cell therapy, effectively eradicates early-stage melanoma and inhibits the progression of pancreatic tumors. Notably, this dual strategy also strengthened the distal tumor control capabilities of adoptive T-cell therapy through the induction of in situ tumor vaccination. This dual therapeutic approach involving bacterial therapy targeting the interior of solid tumors and adoptive T-cell therapy attacking the tumor periphery exhibits potent therapeutic efficacy in achieving the eradication of advanced-stage tumors, including melanoma and hepatocellular carcinoma, by converging attacks from both inside and outside the tumor tissues.